Zhou, J., Zhang, P., Zheng, J., Li, Y., Ma, X., Huang, W. (2026). Lorlatinib as first-line therapy for ALK-positive advanced non-small cell lung cancer: A retrospective, multicenter, real-world study from China.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e20740